Cellular energy sensing and signaling by AMP-activated protein kinase

Cell Biochemistry and Biophysics

Volumn 47, Issue 3, 2007, Pages 332-347

  Winder, William W ^a   Thomson, David M ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

AMPK; Fatty acid oxidation; Glucose uptake; LKB1 STRAD MO25; Protein synthesis; Type 2 diabetes

Indexed keywords

ADENOSINE PHOSPHATE; ADENYLATE KINASE;

BIOLOGICAL MODEL; ENERGY TRANSFER; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ADENOSINE MONOPHOSPHATE; ADENYLATE KINASE; ENERGY TRANSFER; ENZYME ACTIVATION; FEEDBACK; MAP KINASE SIGNALING SYSTEM; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 34548301663     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-007-0008-7     Document Type: Review

References (214)

1. Abbud, W., Habinowski, S., Zhang, J. Z., Kendrew, J., Elkairi, F. S., Kemp, B. E., Witters, L. A., & Ismail-Beigi, F. (2000). Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Archives of Biochemistry and Biophysics, 380, 347-352.
2. Abu,-Elheiga, L., Brinkley, W. R., Zhong, L., Chirala, S. S., Woldegiorgis, G., Wakil, & SJ (2000). The subcellular localization of acetyl-CoA carboxylase 2. Proceedings of National Academic Sciences of the United States of America, 97, 1444-1449.
3. Adams, J., Chen, Z. P., Van Denderen, B. J., Morton, C. J., Parker, M. W., Witters, L. A., Stapleton, D., & Kemp, B. E. (2004). Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site. Protein Science, 13, 155-165.
4. Ai, H., Ihlemann, J., Hellsten, Y., Lauritzen, H. P., Hardie, D. G., Galbo, H., & Ploug, T. (2002). Effect of fiber type and nutritional state on AICAR- and contraction-stimulated glucose transport in rat muscle. American Journal of Physiology. Endocrinology and Metabolism, 282, E1291-1300.
5. Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006). LKB1-dependent signaling pathways. Annual Review of Biochemistry, 75, 137-163.
6. Altarejos, J. Y., Taniguchi, M., Clanachan, A. S., & Lopaschuk, G. D. (2005). Myocardial ischemia differentially regulates LKB1 and an alternate 5′-AMP-activated protein kinase kinase. The Journal of Biological Chemistry, 280, 183-190.
7. Andersson, U., Filipsson, K., Abbott, C. R., Woods, A., Smith, K., Bloom, S. R., Carling, D., & Small, C. J. (2004). AMP-activated protein kinase plays a role in the control of food intake. The Journal of Biological Chemistry, 279, 12005-12008.
8. Barnes, B. R., & Zierath, J. R. (2005). Role of AMP-activated protein kinase in the control of glucose homeostasis. Current Molecular Medicine, 5, 341-348.
9. Baron, S. J., Li, J., Russell, R. R., 3rd, Neumann, D., Miller, E. J., Tuerk, R., Wallimann, T., Hurley, R. L., Witters, L. A., & Young, L. H. (2005). Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circulation Research, 96, 337-345.
10. Bateman, A. (1997). The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends in Biochemical Sciences, 22, 12-13.
11. Beauloye, C., Marsin, A. S., Bertrand, L., Krause, U., Hardie, D. G., Vanoverschelde, J. L., & Hue, L. (2001). Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Letters, 505, 348-352.
12. Beckers, A., Organe, S., Timmermans, L., Vanderhoydonc, F., Deboel, L., Derua, R., Waelkens, E., Brusselmans, K., Verhoeven, G., & Swinnen, J. V. (2006). Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Molecular Cancer Therapeutics, 5, 2211-2217.
13. Bergeron, R., Previs, S. F., Cline, G. W., Perret, P., Russell, R. R., 3rd, Young, L. H., & Shulman, G. I. (2001). Effect of 5-aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes, 50, 1076-1082.
14. Bergeron, R., Russell, R. R., 3rd, Young, L. H., Ren, J. M., Marcucci, M., Lee, A., & Shulman, G. I. (1999). Effect of AMPK activation on muscle glucose metabolism in conscious rats. The American Journal of Physiology, 276, E938-944.
15. Birk, J. B., & Wojtaszewski, J. F. (2006). Predominant {alpha}2/{beta}2/{gamma}3 AMPK Activation during exercise in human skeletal muscle. The Journal Physiology, 577, 1021-1032.
16. Bolster, D. R., Crozier, S. J., Kimball, S. R., & Jefferson, L. S. (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. The Journal of Biological Chemistry, 277, 23977-23980.
17. Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care, 29, 1990-1991.
18. Brownsey, R. W., Boone, A. N., Elliott, J. E., Kulpa, J. E., & Lee, W. M. (2006). Regulation of acetyl-CoA carboxylase. Biochemical Society Transactions, 34, 223-227.
19. Brozinick, J. T. Jr., & Birnbaum, M. J. (1998). Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle. The Journal of Biological Chemistry, 273, 14679-14682.
20. Buhl, E. S., Jessen, N., Pold, R., Ledet, T., Flyvbjerg, A., Pedersen, S. B., Pedersen, O., Schmitz, O., & Lund, S. (2002). Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes, 51, 2199-2206.
21. Carlson, C. L., & Winder, W. W. (1999). Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. Journal of Applied Physiology, 86, 669-674.
22. Chen, Z. P., McConell, G. K., Michell, B. J., Snow, R. J., Canny, B. J., & Kemp, B. E. (2000). AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. American Journal of Physiology. Endocrinology and Metabolism, 279, E1202-1206.
23. Cheng, S. W., Fryer, L. G., Carling, D., & Shepherd, P. R. (2004). Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. The Journal of Biological Chemistry, 279, 15719-15722.
24. Cheung, P. C., Salt, I. P., Davies, S. P., Hardie, D. G., & Carling, D. (2000). Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. The Biochemical Journal, 346(Pt 3), 659-669.
25. Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R., Zhao, G., Marsh, K., Kym, P., Jung, P., Camp, H. S., & Frevert, E. (2006). Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabolism, 3, 403-416.
26. Coven, D. L., Hu, X., Cong, L., Bergeron, R., Shulman, G. I., Hardie, D. G., & Young, L. H. (2003). Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. American Journal of Physiology. Endocrinology and Metabolism, 285, E629-636.
27. Cusi, K., Consoli, A., & DeFronzo, R. A. (1996). Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism, 81, 4059-4067.
28. Daniel, T., & Carling, D. (2002). Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. The Journal of Biological Chemistry, 277, 51017-51024.
29. Dasilva Xavier, G., Leclerc, I., Varadi, A., Tsuboi, T., Moule, S. K., & Rutter, G. A. (2003). Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. The Biochemical Journal, 371, 761-774.
30. Daval, M., Diot-Dupuy, F., Bazin, R., Hainault, I., Viollet, B., Vaulont, S., Hajduch, E., Ferre, P., & Foufelle, F. (2005). Antilipolytic action of AMP-activated protein kinase in rodent adipocytes. The Journal of Biological Chemistry, 280, 25250-25257.
31. Daval, M., Foufelle, F., & Ferre, P. (2006). Functions of AMP-activated protein kinase in adipose tissue. Journal of Physiology, 574, 55-62.
32. Davies, S. P., Helps, N. R., Cohen, P. T., & Hardie, D. G. (1995). 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Letters, 377, 421-425.
33. Davies, S. P., Sim, A. T., & Hardie, D. G. (1990). Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. European Journal of Biochemistry, 187, 183-190.
34. Derave, W., Ai, H., Ihlemann, J., Witters, L. A., Kristiansen, S., Richter, E. A., & Ploug, T. (2000). Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. Diabetes, 49, 1281-1287.
35. Dixon, R., Gourzis, J., McDermott, D., Fujitaki, J., Dewland, P., & Gruber, H. (1991). AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. Journal of Clinical Pharmacology, 31, 342-347.
36. Dyck, J. R., Gao, G., Widmer, J., Stapleton, D., Fernandez, C. S., Kemp, B. E., & Witters, L. A. (1996). Regulation of 5′-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. The Journal of Biological Chemistry, 271, 17798-17803.
37. Dyck, J. R., Kudo, N., Barr, A. J., Davies, S. P., Hardie, D. G., & Lopaschuk, G. D. (1999). Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. European Journal of Biochemistry, 262, 184-190.
38. Ellingson, W. J., Chesser, D. G., & Winder, W. W. (2006). The effects of 3-phosphoglycerate and other metabolites on the activation of Amp-activated protein kinase by Lkb1-Strad-Mo25. American Journal of Physiology. Endocrinology and Metabolism, 292, E400-407.
39. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-1305.
40. Fiedler, M., Zierath, J. R., Selen, G., Wallberg-Henriksson, H., Liang, Y., & Sakariassen, K. S. (2001). 5-aminoimidazole-4-carboxy-amide-1-beta- D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAy-CETP mice. Diabetologia, 44, 2180-2186.
41. Fisher, J. S., Gao, J., Han, D. H., Holloszy, J. O., & Nolte, L. A. (2002). Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. American Journal of Physiology. Endocrinology and Metabolism, 282, E18-23.
42. Frederich, M., & Balschi, J. A. (2002). The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart. The Journal of Biological Chemistry, 277, 1928-1932.
43. Frederich, M., Zhang, L., & Balschi, J. A. (2005). Hypoxia and AMP independently regulate AMP-activated protein kinase activity in heart. American Journal of Physiology. Heart and Circulatory Physiology, 288, H2412-2421.
44. Fryer, L. G., Hajduch, E., Rencurel, F., Salt, I. P., Hundal, H. S., Hardie, D. G., & Carling, D. (2000). Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes, 49, 1978-1985.
45. Fryer, L. G., Parbu-Patel, A., & Carling, D. (2002). The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. The Journal of Biological Chemistry, 277, 25226-25232.
46. Fujii, N., Aschenbach, W. G., Musi, N., Hirshman, M. F., & Goodyear, L. J. (2004). Regulation of glucose transport by the AMP-activated protein kinase. The Proceedings of the Nutrition Society, 63, 205-210.
47. Fujii, N., Jessen, N., Goodyear, L. J. (2006). AMP-activated protein kinase and the regulation of glucose transport. American Journal of Physiology. Endocrinology and Metabolism, 291, E867-877.
48. Gamble, J., & Lopaschuk, G. D. (1997). Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism, 46, 1270-1274.
49. Garton, A. J., Campbell, D. G., Carling, D., Hardie, D. G., Colbran, R. J., & Yeaman, S. J. (1989). Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. European Journal of Biochemistry, 179, 249-254.
50. Gonzalez, A. A., Kumar, R., Mulligan, J. D., Davis, A. J., Weindruch, R., & Saupe, K. W. (2004). Metabolic adaptations to fasting and chronic caloric restriction in heart, muscle, and liver do not include changes in AMPK activity. American Journal of Physiology. Endocrinology and Metabolism, 287, E1032-1037.
51. Halseth, A. E., Ensor, N. J., White, T. A., Ross, S. A., & Gulve, E. A. (2002). Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochemical and Biophysical Research Communications, 294, 798-805.
52. Hancock, C. R., Janssen, E., & Terjung, R. L. (2006). Contraction-mediated phosphorylation of AMPK is lower in skeletal muscle of adenylate kinase-deficient mice. Journal of Applied Physiology, 100, 406-413.
53. Hardie, D. G. (1999). Roles of the AMP-activated/SNF1 protein kinase family in the response to cellular stress. Biochemical Society Symposium, 64, 13-27.
54. Hardie, D. G. (2003). Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 144, 5179-5183.
55. Hardie, D. G. (2004). AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Medicine Science Sports Exercise, 36, 28-34.
56. Hardie, D. G. (2006). AMP-activated protein kinase as a drug target. Annual Review of Pharmacology and Toxicology, 47, 185-210.
57. Hardie, D. G., & Carling, D. (1997). The AMP-activated protein kinase - fuel gauge of the mammalian cell? European Journal of Biochemistry, 246, 259-273.
58. Hardie, D. G., & Hawley, S. A. (2001). AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays, 23, 1112-1119.
59. Hardie, D. G., & Sakamoto, K. (2006). AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda), 21, 48-60.
60. Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Makela, T. P., Alessi, D. R., & Hardie, D. G. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of Biology, 2, 28.
61. Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., & Hardie, D. G. (1996). Characterization of the AMP-activated protein kinase kinase from rat liver, identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. The Journal of Biological Chemistry, 271, 27879-27887.
62. Hawley, S. A., Gadalla, A. E., Olsen, G. S., & Hardie, D. G. (2002). The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes, 51, 2420-2425.
63. Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005). Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metabolism, 2, 9-19.
64. Hay, N., & Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes & Development, 18, 1926-1945.
65. Hayashi, T., Hirshman, M. F., Kurth, E. J., Winder, W. W., & Goodyear, L. J. (1998). Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes, 47, 1369-1373.
66. Holloway, G. P., Bezaire, V., Heigenhauser, G. J., Tandon, N. N., Glatz, J. F., Luiken, J. J., Bonen, A., & Spriet, L. L. (2006). Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in human skeletal muscle during aerobic exercise. The Journal of Physiology, 571, 201-210.
67. Holmes, B. F., Kurth-Kraczek, E. J., & Winder, W. W. (1999). Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. Journal of Applied Physiology, 87, 1990-1995.
68. Holmes, B. F., Sparling, D. P., Olson, A. L., Winder, W. W., & Dohm, G. L. (2005). Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase. American Journal of Physiology. Endocrinology and Metabolism, 289, E1071-1076.
69. Hopkins, T. A., Dyck, J. R., & Lopaschuk, G. D. (2003). AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochemical Society Transactions, 31, 207-212.
70. Horman, S., Browne, G., Krause, U., Patel, J., Vertommen, D., Bertrand, L., Lavoinne, A., Hue, L., Proud, C., & Rider, M. (2002). Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Current Biology, 12, 1419-1423.
71. Horman, S., Vertommen, D., Heath, R., Neumann, D., Mouton, V., Woods, A., Schlattner, U., Wallimann, T., Carling, D., Hue, L., & Rider, M. H. (2006). Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. The Journal of Biological Chemistry, 281, 5335-5340.
72. Hother-Nielsen, O., Schmitz, O., Andersen, P. H., Beck-Nielsen, H., & Pedersen, O. (1989). Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinologica (Copenh), 120, 257-265.
73. Hurley, R. L., Barre, L. K., Wood, S. D., Anderson, K. A., Kemp, B. E., Means, A. R., & Witters, L. A. (2006). Regulation of AMP-activated protein kinase by multi-site phosphorylation in response to agents that elevate cellular cAMP. The Journal of Biological Chemistry, 281, 36662-36672.
74. Hurst, D., Taylor, E. B., Cline, T. D., Greenwood, L. J., Compton, C. L., Lamb, J. D., & Winder, W. W. (2005). AMP-activated protein kinase kinase activity and phosphorylation of AMP-activated protein kinase in contracting muscle of sedentary and endurance-trained rats. American Journal of Physiology. Endocrinology and Metabolism, 289, E710-715.
75. Hutber, C. A., Hardie, D. G., & Winder, W. W. (1997). Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. The American Journal of Physiology, 272, E262-266.
76. Hutchinson, D. S., & Bengtsson, T. (2006). AMP-activated protein kinase activation by adrenoceptors in L6 skeletal muscle cells: mediation by alpha1-adrenoceptors causing glucose uptake. Diabetes, 55, 682-690.
77. Hutchinson, D. S., Chernogubova, E., Dallner, O. S., Cannon, B., & Bengtsson, T. (2005). Beta-adrenoceptors, but not alpha-adrenoceptors, stimulate AMP-activated protein kinase in brown adipocytes independently of uncoupling protein-1. Diabetologia, 48, 2386-2395.
78. Igata, M., Motoshima, H., Tsuruzoe, K., Kojima, K., Matsumura, T., Kondo, T., Taguchi, T., Nakamaru, K., Yano, M., Kukidome, D., Matsumoto, K., Toyonaga, T., Asano, T., Nishikawa, T., & Araki, E. (2005). Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circulation Research, 97, 837-844.
79. Iglesias, M. A., Ye, J. M., Frangioudakis, G., Saha, A. K., Tomas, E., Ruderman, N. B., Cooney, G. J., & Kraegen, E. W. (2002). AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes, 51, 2886-2894.
80. Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M., & Esumi, H. (2001). Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside, in a human hepatocellular carcinoma cell line. Biochemical and Biophysical Research Communications, 287, 562-567.
81. Ingebritsen, T. S., Stewart, A. A., & Cohen, P. (1983). The protein phosphatases involved in cellular regulation. 6. Measurement of type-1 and type-2 protein phosphatases in extracts of mammalian tissues; an assessment of their physiological roles. European Journal of Biochemistry, 132, 297-307.
82. Inoki, K., Zhu, T., & Guan, K. L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590.
83. Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998). Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. The New England Journal of Medicine, 338, 867-872.
84. Iseli, T. J., Walter, M., van Denderen, B. J., Katsis, F., Witters, L. A., Kemp, B. E., Michell, B. J., & Stapleton, D. (2005). AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). The Journal of Biological Chemistry, 280, 13395-13400.
85. Jessen, N., Pold, R., Buhl, E. S., Jensen, L. S., Schmitz, O., & Lund, S. (2003). Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. Journal of Applied Physiology, 94, 1373-1379.
86. Ju, J. S., Gitcho, M. A., Casmaer, C. A., Patil, P. B., Han, D. G., Spencer, S. A., & Fisher, J. S. (2007). Potentiation of insulin-stimulated glucose transport by the AMP-activated protein kinase. American Journal of Physiology. Cell Physiology, 292, C564-572.
87. Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism, 1, 15-25.
88. Kawanaka, K., Nolte, L. A., Han, D. H., Hansen, P. A., & Holloszy, J. O. (2000). Mechanisms underlying impaired GLUT-4 translocation in glycogen-supercompensated muscles of exercised rats. American Journal of Physiology. Endocrinology and Metabolism, 279, E1311-1318.
89. Kelly, M., Keller, C., Avilucea, P. R., Keller, P., Luo, Z., Xiang, X., Giralt, M., Hidalgo, J., Saha, A. K., Pedersen, B. K., & Ruderman, N. B. (2004). AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochemical and Biophysical Research Communication, 320, 449-454.
90. Kim, M. S., Park, J. Y., Namkoong, C., Jang, P. G., Ryu, J. W., Song, H. S., Yun, J. Y., Namgoong, I. S., Ha, J., Park, I. S., Lee, I. K., Viollet, B., Youn, J. H., Lee, H. K., & Lee, K. U. (2004). Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nature Medicine, 10, 727-733.
91. Kim, J., Solis, R. S., Arias, E. B., & Cartee, G. D. (2004). Postcontraction insulin sensitivity: relationship with contraction protocol, glycogen concentration, and 5′ AMP-activated protein kinase phosphorylation. Journal of Applied Physiology, 96, 575-583.
92. Koh, H. J., Arnolds, D. E., Fujii, N., Tran, T. T., Rogers, M. J., Jessen, N., Li, Y., Liew, C. W., Ho, R. C., Hirshman, M. F., Kulkarni, R. N., Kahn, C. R., & Goodyear, L. J. (2006). Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Molecular and Cellular Biology, 26, 8217-8227.
93. Koistinen, H. A., Galuska, D., Chibalin, A. V., Yang, J., Zierath, J. R., Holman, G. D., Wallberg-&, Henriksson, H. (2003). 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes, 52, 1066-1072.
94. Kola, B., Hubina, E., Tucci, S. A., Kirkham, T. C., Garcia, E. A., Mitchell, S. E., Williams, L. M., Hawley, S. A., Hardie, D. G., Grossman, A. B., & Korbonits, M. (2005). Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. The Journal of Biological Chemistry, 280, 25196-25201.
95. Kovacic, S., Soltys, C. L., Barr, A. J., Shiojima, I., Walsh, K., & Dyck, J. R. (2003). Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. The Journal of Biological Chemistry, 278, 39422-39427.
96. Kramer, H. F., Witczak, C. A., Fujii, N., Jessen, N., Taylor, E. B., Arnolds, D. E., Sakamoto, K., Hirshman, M. F., & Goodyear, L. J. (2006). Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes, 55, 2067-2076.
97. Kudo, N., Gillespie, J. G., Kung, L., Witters, L. A., Schulz, R., Clanachan, A. S., & Lopaschuk, G. D. (1996). Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochimica et Biophysica Acta, 1301, 67-75.
98. Kurth,-Kraczek, E. J., Hirshman, M. F., Goodyear, L. J., & Winder, W. W. (1999). 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes, 48, 1667-1671.
99. Lang, T., Yu, L., Tu, Q., Jiang, J., Chen, Z., Xin, Y., Liu, G., & Zhao, S. (2000). Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma 2 subunit of 5′-AMP-activated protein kinase, to human chromosome 7q36. Genomics, 70, 258-263.
100. Lebrasseur, N. K., Kelly, M., Tsao, T. S., Farmer, S. R., Saha, A. K., & Ruderman, N. B., Tomas, E. (2006). Thiazolidinediones can rapidly activate AMP-activated protein kinase (AMPK) in mammalian tissues. American Journal of Physiology. Endocrinology and Metabolism, 291, E175-181.
101. Leclerc, I., & Rutter, G. A. (2004). AMP-activated protein kinase: a new beta-cell glucose sensor? Regulation by amino acids and calcium ions. Diabetes, 53(Suppl 3), S67-74.
102. Leclerc, I., Woltersdorf, W. W., da Silva Xavier, G., Rowe, R. L., Cross, S. E., Korbutt, G. S., Rajotte, R. V., Smith, R., & Rutter, G. A. (2004). Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. American Journal of Physiology. Endocrinology and Metabolism, 286, E1023-1031.
103. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). The Journal of Biological Chemistry, 270, 12953-12956.
104. Lessard, S. J., Chen, Z. P., Watt, M. J., Hashem, M., Reid, J. J., Febbraio, M. A., Kemp, B. E., & Hawley, J. A. (2006). Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism, 290, E251-257.
105. Leung, J. M., Stanley, T., 3rd, Mathew, J., Curling, P., Barash, P., Salmenpera, M., Reves, J. G., Hollenberg, M., & Mangano, D. T. (1994). An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. Anesthesia and analgesia, 78, 420-434.
106. Lihn, A. S., Jessen, N., Pedersen, S. B., Lund, S., & Richelsen, B. (2004). AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochemical and Biophysical Research Communications, 316, 853-858.
107. Lizcano, J. M., Goransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Makela, T. P., Hardie, D. G., & Alessi, D. R. (2004). LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. The EMBO Journal, 23, 833-843.
108. Longnus, S. L., Segalen, C., Giudicelli, J., Sajan, M. P., Farese, R. V. Van, & Obberghen, E. (2005). Insulin signalling downstream of protein kinase B is potentiated by 5′AMP-activated protein kinase in rat hearts in vivo. Diabetologia, 48, 2591-2601.
109. MacDonald, C., Wojtaszewski, J. F., Pedersen, B. K., Kiens, B., & Richter, E. A. (2003). Interleukin-6 release from human skeletal muscle during exercise: relation to AMPK activity. Journal of Applied Physiology, 95, 2273-2277.
110. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., & Matsuzawa, Y. (2001). PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 50, 2094-2099.
111. Mahlapuu, M., Johansson, C., Lindgren, K., Hjalm, G., Barnes, B. R., Krook, A., Zierath, J. R., Andersson, L., & Marklund, S. (2004). Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. American Journal of Physiology. Endocrinology Metabolism, 286, E194-200.
112. Marley, A. E., Sullivan, J. E., Carling, D., Abbott, W. M., Smith, G. J., Taylor, I. W., Carey, F., & Beri, R. K. (1996). Biochemical characterization and deletion analysis of recombinant human protein phosphatase 2C alpha. The Biochemical Journal, 320(Pt 3), 801-806.
113. Marsin, A. S., Bertrand, L., Rider, M. H., Deprez, J., Beauloye, C., Vincent, M. F., Van den Berghe, G., Carling, D., & Hue, L. (2000). Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Current Biology, 10, 1247-1255.
114. Merrill, G. F., Kurth, E. J., Hardie, D. G., & Winder, W. W. (1997). AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. The American Journal of Physiology, 273, E1107-1112.
115. Merrill, G. F., Kurth, E. J., Rasmussen, B. B., & Winder, W. W. (1998). Influence of malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle. Journal of Applied Physiology, 85, 1909-1914.
116. Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y. B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferre, P., Birnbaum, M. J., Stuck, B. J., & Kahn, B. B. (2004). AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 428, 569-574.
117. Minokoshi, Y., Kim, Y. B., Peroni, O. D., Fryer, L. G., Muller, C., Carling, D., & Kahn, B. B. (2002). Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature, 415, 339-343.
118. Mitchelhill, K. I., Michell, B. J., House, C. M., Stapleton, D., Dyck, J., Gamble, J., Ullrich, C., Witters, L. A., & Kemp, B. E. (1997). Posttranslational modifications of the 5′-AMP-activated protein kinase beta1 subunit. The Journal of Biological Chemistry, 272, 24475-24479.
119. Momcilovic, M., Hong, S. P., Carlson, M. (2006). Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. The Journal of Biological Chemistry, 281, 25336-25343.
120. Moore, F., Weekes, J., & Hardie, D. G. (1991). Evidence that AMP triggers phosphorylation as well as direct allosteric activation of rat liver AMP-activated protein kinase. A sensitive mechanism to protect the cell against ATP depletion. European Journal of Biochemistry, 199, 691-697.
121. Motoshima, H., Goldstein, B. J., Igata, M., & Araki, E. (2006). AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. The Journal of Physiology, 574, 63-71.
122. Mu, J., Brozinick, J. T. Jr., Valladares, O., Bucan, M., & Birnbaum, M. J. (2001). A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Molecular Cell, 7, 1085-1094.
123. Muoio, D. M., Seefeld, K., Witters, L. A., & Coleman, R. A. (1999). AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. The Biochemical Journal, 338(Pt 3), 783-791.
124. Musi, N., & Goodyear, L. J. (2002). Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Current Drug Targets. Immune, Endocrine, and Metabolic Disorders, 2, 119-127.
125. Musi, N., & Goodyear, L. J. (2003). AMP-activated protein kinase and muscle glucose uptake. Acta Physiologica Scandinavica, 178, 337-345.
126. Musi, N., & Goodyear, L. J. (2006). Insulin resistance and improvements in signal transduction. Endocrine, 29, 73-80.
127. Musi, N., Hayashi, T., Fujii, N., Hirshman, M. F., Witters, L. A., & Goodyear, L. J. (2001). AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism, 280, E677-684.
128. Musi, N., Hirshman, M. F., Arad, M., Xing, Y., Fujii, N., Pomerleau, J., Ahmad, F., Berul, C. I., Seidman, J. G., Tian, R., & Goodyear, L. J. (2005). Functional role of AMP-activated protein kinase in the heart during exercise. FEBS Letters, 579, 2045-2050.
129. Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., Moller, D. E., Thorell, A., & Goodyear, L. J. (2002). Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 51, 2074-2081.
130. Namkoong, C., Kim, M. S., Jang, P. G., Han, S. M., Park, H. S., Koh, E. H., Lee, W. J., Kim, J. Y., Park, I. S., Park, J. Y., & Lee, K. U. (2005). Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Diabetes, 54, 63-68.
131. Nielsen, J. N., Jorgensen, S. B., Frosig, C., Viollet, B., Andreelli, F., Vaulont, S., Kiens, B., Richter, E. A., & Wojtaszewski, J. F. (2003). A possible role for AMP-activated protein kinase in exercise-induced glucose utilization: insights from humans and transgenic animals. Biochemical Society Transactions, 31, 186-190.
132. Odland, L. M., Heigenhauser, G. J., Lopaschuk, G. D., & Spriet, L. L. (1996). Human skeletal muscle malonyl-CoA at rest and during prolonged submaximal exercise. The American Journal of Physiology, 270, E541-544.
133. Odland, L. M., Howlett, R. A., Heigenhauser, G. J., Hultman, E., & Spriet, L. L. (1998). Skeletal muscle malonyl-CoA content at the onset of exercise at varying power outputs in humans. The American Journal of
134. Ojuka, E. O., Jones, T. E., Nolte, L. A., Chen, M., Wamhoff, B. R., Sturek, M., & Holloszy, J. O. (2002). Regulation of GLUT4 biogenesis in muscle: evidence for involvement of AMPK and Ca(2+). American Journal of Physiology. Endocrinology and Metabolism, 282, E1008-1013.
135. Owen, M. R., Doran, E., & Halestrap, A. P. (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. The Biochemical Journal, 348(Pt 3), 607-614.
136. Park, S. H., Gammon, S. R., Knippers, J. D., Paulsen, S. R., Rubink, D. S., & Winder, W. W. (2002). Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. Journal of Applied Physiology, 92, 2475-2482.
137. Park, H., Kaushik, V. K., Constant, S., Prentki, M., Przybytkowski, E., Ruderman, N. B., & Saha, A. K. (2002). Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. The Journal of Biological Chemistry, 277, 32571-32577.
138. Pold, R., Jensen, L. S., Jessen, N., Buhl, E. S., Schmitz, O., Flyvbjerg, A., Fujii, N., Goodyear, L. J., Gotfredsen, C. F., Brand, C. L., & Lund, S. (2005). Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes, 54, 928-934.
139. Ponticos, M., Lu, Q. L., Morgan, J. E., Hardie, D. G., Partridge, T. A., & Carling, D. (1998). Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. The EMBO Journal, 17, 1688-1699.
140. Rasmussen, B. B., & Winder, W. W. (1997). Effect of exercise intensity on skeletal muscle malonyl-CoA and acetyl-CoA carboxylase. Journal of Applied Physiology, 83, 1104-1109.
141. Rattan, R., Giri, S., Singh, A. K., & Singh, I. (2005). 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. The Journal of Biological Chemistry, 280, 39582-39593.
142. Ravnskjaer, K., Boergesen, M., Dalgaard, L. T., & Mandrup, S. (2006). Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. Journal of Molecular Endocrinology, 36, 289-299.
143. Reiter, A. K., Bolster, D. R., Crozier, S. J., Kimball, S. R., & Jefferson, L. S. (2005). Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. American Journal of Physiology. Endocrinology and Metabolism, 288, E980-988.
144. Richter, E. A., Derave, W., & Wojtaszewski, J. F. (2001). Glucose, exercise and insulin: emerging concepts. The Journal of Physiology, 535, 313-322.
145. Richter, E. A., Wojtaszewski, J. F., Kristiansen, S., Daugaard, J. R., Nielsen, J. N., Derave, W., & Kiens, B. (2001). Regulation of muscle glucose transport during exercise. International Journal of Sport Nutrition and Exercise Metabolism, 11(Suppl), S71-77.
146. Roepstorff, C., Halberg, N., Hillig, T., Saha, A. K., Ruderman, N. B., Wojtaszewski, J. F., Richter, E. A., & Kiens, B. (2005). Malonyl-CoA and carnitine in regulation of fat oxidation in human skeletal muscle during exercise. American Journal of Physiology. Endocrinology and Metabolism, 288, E133-142.
147. Rosen, E. D., & Spiegelman, B. M. (2001). PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. The Journal of Biological Chemistry, 276, 37731-37734.
148. Ruderman, N. B., Park, H., Kaushik, V. K., Dean, D., Constant, S., Prentki, M., & Saha, A. K. (2003). AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiologica Scandinavica, 178, 435-442.
149. Russell, R., 3rd (2003). The Role of AMP-activated protein kinase in fuel selection by the stressed heart. Current Hypertension Reports, 5, 459-465.
150. Russell, R. R., 3rd, Bergeron, R., Shulman, G. I., & Young, L. H. (1999). Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. The American Journal of Physiology, 277, H643-649.
151. Russell, R. R., 3rd, Li, J., Coven, D. L., Pypaert, M., Zechner, C., Palmeri, M., Giordano, F. J., Mu, J., Birnbaum, M. J., & Young, L. H. (2004). AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. The Journal of Clinical Investigation, 114, 495-503.
152. Rutter, G. A., Da Silva, Xavier, G., & Leclerc, I. (2003). Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. The Biochemical Journal, 375, 1-16.
153. Sakamoto, K., Goransson, O., Hardie, D. G., & Alessi, D. R. (2004). Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. American Journal of Physiology. Endocrinology and Metabolism, 287, E310-317.
154. Sakamoto, K., McCarthy, A., Smith, D., Green, K. A., Grahame, Hardie, D., Ashworth, A., & Alessi, D. R. (2005). Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. The EMBO Journal, 24, 1810-1820.
155. Sakamoto, K., Zarrinpashneh, E., Budas, G. R., Pouleur, A. C., Dutta, A., Prescott, A. R., Vanoverschelde, J. L., Ashworth, A., Jovanovic, A., Alessi, D. R., & Bertrand, L. (2006). Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKα2 but not AMPKα1. American Journal of Physiology. Endocrinology and Metabolism, 290, E780-788.
156. Sakoda, H., Ogihara, T., Anai, M., Fujishiro, M., Ono, H., Onishi, Y., Katagiri, H., Abe, M., Fukushima, Y., Shojima, N., Inukai, K., Kikuchi, M., Oka, Y., & Asano, T. (2002). Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. American Journal of Physiology. Endocrinology and Metabolism, 282, E1239-1244.
157. Salt, I., Celler, J. W., Hawley, S. A., Prescott, A., Woods, A., Carling, D., & Hardie, D. G. (1998). AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. The Biochemical Journal, 334(Pt 1), 177-187.
158. Salt, I. P., Connell, J. M., & Gould, G. W. (2000). 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes, 49, 1649-1656.
159. Salt, I. P., Johnson, G., Ashcroft, S. J., & Hardie, D. G. (1998). AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. The Biochemical Journal, 335(Pt 3), 533-539.
160. Sambandam, N., & Lopaschuk, G. D. (2003). AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Progress in Lipid Research, 42, 238-256.
161. Scott, J. W., Hawley, S. A., Green, K. A., Anis, M., Stewart, G., Scullion, G. A., Norman, D. G., & Hardie, D. G. (2004). CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. The Journal of Clinical Investigation, 113, 274-284.
162. Sell, H., Dietze-Schroeder, D., Eckardt, K., & Eckel, J. (2006). Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochemical and Biophysical Research Communications, 343, 700-706.
163. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91-99.
164. Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proceedings of National Academic Sciences of the United States of America, 101, 3329-3335.
165. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M., & Cantley, L. C. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-1646.
166. Smith, J. L., Patil, P. B., & Fisher, J. S. (2005). AICAR and hyperosmotic stress increase insulin-stimulated glucose transport. Journal of Applied Physiology, 99, 877-883.
167. Soltys, C. L., Kovacic, S., & Dyck, J. R. (2006). Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. American Journal of Physiology. Heart and Circulatory Physiology, 290, H2472-2479.
168. Song, X. M., Fiedler, M., Galuska, D., Ryder, J. W., Fernstrom, M., Chibalin, A. V., Wallberg-Henriksson, H., & Zierath, J. R. (2002). 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia, 45, 56-65.
169. Sponarova, J., Mustard, K. J., Horakova, O., Flachs, P., Rossmeisl, M., Brauner, P., Bardova, K., Thomason-Hughes, M., Braunerova, R., Janovska, P., Hardie, D. G., & Kopecky, J. (2005). Involvement of AMP-activated protein kinase in fat depot-specific metabolic changes during starvation. FEBS Letters, 579, 6105-6110.
170. Stein, S. C., Woods, A., Jones, N. A., Davison, M. D., & Carling, D. (2000). The regulation of AMP-activated protein kinase by phosphorylation. The Biochemical Journal, 345(Pt 3), 437-443.
171. Stephens, T. J., Chen, Z. P., Canny, B. J., Michell, B. J., Kemp, B. E., & McConell, G. K. (2002). Progressive increase in human skeletal muscle AMPKalpha2 activity and ACC phosphorylation during exercise. American Journal of Physiology. Endocrinology and Metabolism, 282, E688-694.
172. Stoppani, J., Hildebrandt, A. L., Sakamoto, K., Cameron-Smith, D., Goodyear, L. J., & Neufer, P. D. (2002). AMP-activated protein kinase activates transcription of the UCP3 and HKII genes in rat skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism, 283, E1239-1248.
173. Sullivan, J. E., Brocklehurst, K. J., Marley, A. E., Carey, F., Carling, D., & Beri, R. K. (1994). Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Letters, 353, 33-36.
174. Suter, M., Riek, U., Tuerk, R., Schlattner, U., Wallimann, T., & Neumann, D. (2006). Dissecting the role of 5′-AMP for allosteric stimulation, activation and deactivation of AMP-activated protein kinase. The Journal of Biological Chemistry, 281, 32207-32216.
175. Swinnen, J. V., Beckers, A., Brusselmans, K., Organe, S., Segers, J., Timmermans, L., Vanderhoydonc, F., Deboel, L., Derua, R., Waelkens, E., De Schrijver, E., Van de Sande, T., Noel, A., Foufelle, F., & Verhoeven, G. (2005). Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Research, 65, 2441-2448.
176. Taylor, E. B., Ellingson, W. J., Lamb, J. D., Chesser, D. G., Compton, C. L., & Winder, W. W. (2006). Evidence against regulation of AMP-activated protein kinase and LKB1/STRAD/MO25 activity by creatine phosphate. American Journal of Physiology. Endocrinology and Metabolism, 290, E661-669.
177. Taylor, E. B., Ellingson, W. J., Lamb, J. D., Chesser, D. G., & Winder, W. W. (2005). Long-chain acyl-CoA esters inhibit phosphorylation of AMP-activated protein kinase at threonine-172 by LKB1/STRAD/MO25. American Journal of Physiology. Endocrinology and Metabolism, 288, E1055-1061.
178. Taylor, E. B., Lamb, J. D., Hurst, R. W., Chesser, D. G., Ellingson, W. J., Greenwood, L. J., Porter, B. B., Herway, S. T., & Winder, W. W. (2005). Endurance training increases skeletal muscle LKB1 and PGC-1alpha protein abundance: Effects of time and intensity. American Journal of Physiology. Endocrinology and Metabolism, 289, E960-968.
179. Thomson, D. M., Porter, B. B., Tall, J. H., Kim, H. J., Barrow, J. R., & Winder, W. W. (2007). Skeletal muscle and heart LKB1 deficiency causes decreased voluntary running and reduced muscle mitochondrial marker enzyme expression in mice. American Journal of Physiology. Endocrinology and Metabolism, 292, E196-202.
180. Tomas, E., Tsao, T. S., Saha, A. K., Murrey, H. E., Zhang, Cc, C., Itani, S. I., Lodish, H. F., & Ruderman, N. B. (2002). Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proceedings of National Academic Sciences of the United States of America, 99, 16309-16313.
181. Treebak, J. T., Glund, S., Deshmukh, A., Klein, D. K., Long, Y. C., Jensen, T. E., Jorgensen, S. B., Viollet, B., Andersson, L., Neumann, D., Wallimann, T., Richter, E. A., Chibalin, A. V., Zierath, J. R., & Wojtaszewski, J. F. (2006). AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. Diabetes, 55, 2051-2058.
182. Vavvas, D., Apazidis, A., Saha, A. K., Gamble, J., Patel, A., Kemp, B. E., Witters, L. A., & Ruderman, N. B. (1997). Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. The Journal of Biological Chemistry, 272, 13255-13261.
183. Vincent, M. F., Marangos, P., Gruber, H. E., & Van den Berghe, G. (1991). AICAriboside inhibits gluconeogenesis in isolated rat hepatocytes. Advances in Experimental Medicine and Biology, 309B, 359-362.
184. Viollet, B., Andreelli, F., Jorgensen, S. B., Perrin, C., Flamez, D., Mu, J., Wojtaszewski, J. F., Schuit, F. C., Birnbaum, M., Richter, E., Burcelin, R., & Vaulont, S. (2003). Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochemical Society Transactions, 31, 216-219.
185. Viollet, B., Andreelli, F., Jorgensen, S. B., Perrin, C., Geloen, A., Flamez, D., Mu, J., Lenzner, C., Baud, O., Bennoun, M., Gomas, E., Nicolas, G., Wojtaszewski, J. F., Kahn, A., Carling, D., Schuit, F. C., Birnbaum, M. J., Richter, E. A., Burcelin, R., & Vaulont, S. (2003). The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. The Journal of Clinical Investigation, 111, 91-98.
186. Warden, S. M., Richardson, C., O'Donnell, J. Jr., Stapleton, D., Kemp, B. E., & Witters, L. A. (2001). Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. The Biochemical Journal, 354, 275-283.
187. Winder, W. W. (2000). AMP-activated protein kinase: possible target for treatment of type 2 diabetes. Diabetes Technology & Therapeutics, 2, 441-448.
188. Winder, W. W. (2001). Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. Journal of Applied Physiology, 91, 1017-1028.
189. Winder, W. W., & Hardie, D. G. (1996). Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. The American Journal of Physiology, 270, E299-304.
190. Winder, W. W., & Hardie, D. G. (1999). AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. The American Journal of Physiology, 277, E1-10.
191. Winder, W. W., Holmes, B. F., Rubink, D. S., Jensen, E. B., Chen, M., & Holloszy, J. O. (2000). Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. Journal of Applied Physiology, 88, 2219-2226.
192. Winder, W. W., Wilson, H. A., Hardie, D. G., Rasmussen, B. B., Hutber, C. A., Call, G. B., Clayton, R. D., Conley, L. M., Yoon, S., & Zhou, B. (1997). Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. Journal of Applied Physiology, 82, 219-225.
193. Witters, L. A., Gao, G., Kemp, B. E., & Quistorff, B. (1994). Hepatic 5′-AMP-activated protein kinase: zonal distribution and relationship to acetyl-CoA carboxylase activity in varying nutritional states. Archives of Biochemistry and Biophysics, 308, 413-419.
194. Witters, L. A., & Kemp, B. E. (1992). Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5′-AMP-activated protein kinase. The Journal of Biological Chemistry, 267, 2864-2867.
195. Witters, L. A., Kemp, B. E., & Means, A. R. (2006). Chutes and ladders: the search for protein kinases that act on AMPK. Trends in Biochemical Sciences, 31, 13-16.
196. Wojtaszewski, J. F., MacDonald, C., Nielsen, J. N., Hellsten, Y., Hardie, D. G., Kemp, B. E., Kiens, B., & Richter, E. A. (2003). Regulation of 5′AMP-activated protein kinase activity and substrate utilization in exercising human skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism, 284, E813-822.
197. Wojtaszewski, J. F., Nielsen, P., Hansen, B. F., Richter, E. A., & Kiens, B. (2000). Isoform-specific and exercise intensity-dependent activation of 5′-AMP-activated protein kinase in human skeletal muscle. The Journal of Physiology, 528(Pt 1), 221-226.
198. Wong, K. A., & Lodish HF (2006). A revised model for AMPK structure: The alpha-subunit binds to both the beta-and gamma-subunits but there is no direct binding between beta- and gamma-subunits. The Journal of Biological Chemistry, 281, 36434-36442.
199. Woods, A., Cheung, P. C., Smith, F. C., Davison, M. D., Scott, J., Beri, R. K., & Carling, D. (1996). Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. The Journal of Biological Chemistry, 271, 10282-10290.
200. 2+/ calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metabolism, 2, 21-33.
201. Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003). LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current Biology, 13, 2004-2008.
202. 2+-dependent mechanism in slow-twitch rat soleus muscle. American Journal of Physiology. Endocrinology and Metabolism, 288, E1062-1066.
203. 2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes, 53, 330-335.
204. Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B., & Luo, Z. (2004). AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochemical and Biophysical Research Communications, 321, 161-167.
205. Xie, M., Zhang, D., Dyck, J. R., Li, Y., Zhang, H., Morishima, M., Mann, D. L., Taffet, G. E., Baldini, A., Khoury, D. S., & Schneider, M. D. (2006). A pivotal role for endogenous TGF-{beta}-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proceedings of National Academic Sciences of the United States of America, 103, 17378-17383.
206. Yamaguchi, S., Katahira, H., Ozawa, S., Nakamichi, Y., Tanaka, T., Shimoyama, T., Takahashi, K., Yoshimoto, K., Imaizumi, M. O., Nagamatsu, S., & Ishida, H. (2005). Activators of AMP-activated protein kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-L1 adipocytes. American Journal of Physiology. Endocrinology and Metabolism, 289, E643-649.
207. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B. B., & Kadowaki, T. (2002). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine, 8, 1288-1295.
208. Yeh, J. I., Gulve, E. A., Rameh, L., & Birnbaum, M. J. (1995). The effects of wortmannin on rat skeletal muscle. Dissociation of signaling pathways for insulin- and contraction-activated hexose transport. The Journal of Biological Chemistry, 270, 2107-2111.
209. Young, L. H., Li, J., Baron, S. J., & Russell, R. R. (2005). AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends in Cardiovascular Medicine, 15, 110-118.
210. Yu, H., Fujii, N., Hirshman, M. F., Pomerleau, J. M., & Goodyear, L. J. (2004). Cloning and characterization of mouse 5′-AMP-activated protein kinase gamma3 subunit. American Journal of Physiology. Cell Physiology, 286, C283-292.
211. Yu, X., McCorkle, S., Wang, M., Lee, Y., Li, J., Saha, A. K., Unger, R. H., & Ruderman, N. B. (2004). Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia, 47, 2012-2021.
212. Zang, M., Xu, S., Maitland-Toolan, K. A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T. J., & Cohen, R. A. (2006). Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 55, 2180-2191.
213. Zheng, D., MacLean, P. S., Pohnert, S. C., Knight, J. B., Olson, A. L., Winder, W. W., & Dohm, G. L. (2001). Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. Journal of Applied Physiology, 91, 1073-1083.
214. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., & Moller, D. E. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of Clinical Investigation, 108, 1167-1174.